Alnylam Pharmace. buy Royal Bank of Canada
Summary
This prediction is currently active. The prediction for Alnylam Pharmace. disappoints with a performance of -19.68%. This prediction currently runs until 18.08.24. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Alnylam Pharmace. | -2.331% | -2.331% |
iShares Core DAX® | -0.683% | 1.890% |
iShares Nasdaq 100 | 0.335% | 4.631% |
iShares Nikkei 225® | -1.486% | -2.361% |
iShares S&P 500 | -0.523% | 2.324% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Royal_Bank_of_Canada for Alnylam Pharmace.
Alnylam Pharmace.
14.02.24
14.02.25
15:59
Alnylam Pharmace.
03.11.23
03.11.24
15:59
Alnylam Pharmace.
06.10.23
06.10.24
15:59
Alnylam Pharmace.
12.09.23
12.09.24
15:59
Alnylam Pharmace.
28.08.23
28.08.24
15:59
Alnylam Pharmace.
04.08.23
04.08.24
15:59
Alnylam Pharmace.
25.07.23
25.07.24
15:59